Clinical Trials Browser

Interventional × trametinib × CNS × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Recruiting

165 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase 2 Active not recruiting

10 enrolled 11 charts

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03919071 2026-05-27

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Phase 2 Active not recruiting

58 enrolled

CNS

Astrocytoma, Glioblastoma, Glioma

NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Phase 2 Active not recruiting

114 enrolled

CNS

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

100 enrolled

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

58 enrolled

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT02015117 2026-04-13

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Phase 1 Active not recruiting

10 enrolled

CNS

Brain Neoplasms

NCT04485559 2026-04-13

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Phase 1 Suspended

50 enrolled

CNS

Glioma

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04201457 2026-02-03

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Phase 1/2 Active not recruiting

57 enrolled

CNS

Glioma

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2 Active not recruiting

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05180825 2025-08-08

PLGG - MEKTRIC

Phase 2 Recruiting

134 enrolled

CNS

Astrocytoma

NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Phase 1/2 Recruiting

27 enrolled

CNS

Glioma

NCT03631953 2024-08-06

ALTREM

Phase 1 Recruiting

25 enrolled

CNS

Meningioma

NCT03434262 2024-05-31

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Phase 1 Completed

68 enrolled

CNSLymphoid

Choroid Plexus Carcinoma, Microphthalmia, Isolated, with Coloboma 5, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Lymphoma, Follicular, Medulloblastoma, Meningioma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Oligodendroglioma, Pinealoma, Recurrence, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT03741101 2024-04-11

plexifpc

Phase 2 Unknown

15 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05525273 2024-02-14

Swecranio

Phase 2 Recruiting

25 enrolled

CNS

Craniopharyngioma

NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Phase 2 Completed

151 enrolled 45 charts 1 FDA

CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT03563729 2023-07-13